novo nordisk's semaglutide shows promise in Phase III CKD trial More than 170,000 people in
Description
10.4049/jimmunol.1103801 39
Kroger, A
Your doctor may recommend alternative treatments or dietary adjustments to maintain stability
continued gradual loss remains achievable with consistent adherence
The discomfort typically stems from dehydration and dietary changes rather than the medication
